fusidic acid [Verutex] — Competitive Intelligence Brief

fusidic acid [Verutex] (fusidic acid [Verutex]) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bacterial protein synthesis inhibitor. Area: Infectious diseases.

phase 3 Bacterial protein synthesis inhibitor Elongation factor G Infectious diseases Small molecule

Target snapshot

fusidic acid [Verutex] (fusidic acid [Verutex]) — Hoffmann-La Roche. Fusidic acid inhibits bacterial protein synthesis by binding to the elongation factor G.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
fusidic acid [Verutex] TARGET	fusidic acid [Verutex]	Hoffmann-La Roche	phase 3	Bacterial protein synthesis inhibitor	Elongation factor G
Fusidic Acid 1% M/R Eye Drops	Fusidic Acid 1% M/R Eye Drops	Barzilai Medical Center	marketed	Bacterial protein synthesis inhibitor / Antibiotic	Elongation factor G (EF-G)
Fucidin® cream	Fucidin® cream	LEO Pharma	marketed	Steroid antibiotic	Bacterial elongation factor G (EF-G)
Fusidic Acid 1%	Fusidic Acid 1%	Baxis Pharmaceuticals, Inc.	phase 3	Steroid antibiotic	Bacterial elongation factor G (EF-G)
mupirocin 2% ointment	mupirocin 2% ointment	Philippine Dermatological Society	phase 3	bacterial protein synthesis inhibitor	isoleucyl-tRNA synthetase
CB-183,315	CB-183,315	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	phase 3	Bacterial protein synthesis inhibitor	Bacterial ribosome

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bacterial protein synthesis inhibitor class)

1. Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
2. Hoffmann-La Roche · 1 drug in this class